UNC alum, pharmaceutical exec Fred Eshelman makes another investment: experimental cancer treatment

Posted Apr 28, 2015
Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board. (Triangle Business Journal)

Related: Campus Connections

UNC graduation goes off with minor interruption
Inside a packed Kenan Stadium was a sea of Carolina blue. The 2024 UNC graduating class that went through COVID uncertainty, a tragic shooting, and...
Sun May 19, 2024

After Pandemic and Protests, UNC’s 2024 Class Celebrates Graduation
UNC wrapped up an eventful year on Saturday with an evening commencement ceremony at Kenan Stadium – a day that ended with fireworks, but also...
Sat May 18, 2024

New UNC club rugby coach looks to bring competitive spirit
Joey Rasmus Jr. originally started what would soon become his lifelong passion on a whim. While training for a decathlon walk-on position for UNC’s track...
Fri May 17, 2024

UNC wants to renovate 'The Pit,' an iconic campus space
UNC is renovating "The Pit," an iconic central space on campus. Architects said stormwater drainage has been a problem since "The Pit" was a construction...
Fri May 17, 2024